AAAAAA

   
Results: 1-17 |
Results: 17
Phosphorylation of nucleoside analog antiretrovirals: A review for clinicians
Authors: Stein, DS Moore, KHP
Citation: Ds. Stein et Khp. Moore, Phosphorylation of nucleoside analog antiretrovirals: A review for clinicians, PHARMACOTHE, 21(1), 2001, pp. 11-34
Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers
Authors: Sadler, BM Piliero, PJ Preston, SL Lloyd, PP Lou, Y Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers, AIDS, 15(8), 2001, pp. 1009-1018
Relationship between oxidative burst activity and CD11b expression in neutrophils and monocytes from healthy individuals: Effects of race and gender
Authors: Siddiqi, M Garcia, ZC Stein, DS Denny, TN Spolarics, Z
Citation: M. Siddiqi et al., Relationship between oxidative burst activity and CD11b expression in neutrophils and monocytes from healthy individuals: Effects of race and gender, CYTOMETRY, 46(4), 2001, pp. 243-246
Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects
Authors: Sadler, BM Chittick, GE Polk, RE Slain, D Kerkering, TM Studenberg, SD Lou, Y Moore, KHP Woolley, JL Stein, DS
Citation: Bm. Sadler et al., Metabolic disposition and pharmacokinetics of [C-14]-amprenavir, a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects, J CLIN PHAR, 41(4), 2001, pp. 386-396
Increased incidence of sepsis and altered monocyte functions in severely injured type A - glucose-6-phosphate dehydrogenase-deficient African American trauma patients
Authors: Spolarics, Z Siddiqi, M Siegel, JH Garcia, ZC Stein, DS Ong, H Livingston, DH Denny, T Deitch, EA
Citation: Z. Spolarics et al., Increased incidence of sepsis and altered monocyte functions in severely injured type A - glucose-6-phosphate dehydrogenase-deficient African American trauma patients, CRIT CARE M, 29(4), 2001, pp. 728-736
In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor
Authors: Sadler, BM Gillotin, C Lou, Y Stein, DS
Citation: Bm. Sadler et al., In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor, ANTIM AG CH, 45(3), 2001, pp. 852-856
Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males
Authors: Polk, RE Brophy, DF Israel, DS Patron, R Sadler, BM Chittick, GE Symonds, WT Lou, Y Kristoff, D Stein, DS
Citation: Re. Polk et al., Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males, ANTIM AG CH, 45(2), 2001, pp. 502-508
Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
Authors: Sadler, BM Gillotin, C Lou, Y Eron, JJ Lang, W Haubrich, R Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir, ANTIM AG CH, 45(12), 2001, pp. 3663-3668
Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
Authors: Sadler, BM Gillotin, C Lou, Y Stein, DS
Citation: Bm. Sadler et al., Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing, ANTIM AG CH, 45(1), 2001, pp. 30-37
Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects
Authors: Weller, S Radomski, KM Lou, Y Stein, DS
Citation: S. Weller et al., Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects, ANTIM AG CH, 44(8), 2000, pp. 2052-2060
Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults
Authors: McDowell, JA Lou, Y Symonds, WS Stein, DS
Citation: Ja. Mcdowell et al., Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults, ANTIM AG CH, 44(8), 2000, pp. 2061-2067
Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation
Authors: Peng, AW Milleri, S Stein, DS
Citation: Aw. Peng et al., Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation, ANTIM AG CH, 44(7), 2000, pp. 1974-1976
Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults
Authors: McDowell, JA Chittick, GE Stevens, CP Edwards, KD Stein, DS
Citation: Ja. Mcdowell et al., Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults, ANTIM AG CH, 44(6), 2000, pp. 1686-1690
Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virustype 1 protease inhibitor, in subjects with normal or impaired hepatic function
Authors: Veronese, L Rautaureau, J Sadler, BM Gillotin, C Petite, JP Pillegand, B Delvaux, M Masliah, C Fosse, S Lou, Y Stein, DS
Citation: L. Veronese et al., Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virustype 1 protease inhibitor, in subjects with normal or impaired hepatic function, ANTIM AG CH, 44(4), 2000, pp. 821-826
Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food
Authors: Chittick, GE Gillotin, C McDowell, JA Lou, Y Edwards, KD Prince, WT Stein, DS
Citation: Ge. Chittick et al., Abacavir: Absolute bioavailability, bioequivalence of three oral formulations, and effect of food, PHARMACOTHE, 19(8), 1999, pp. 932-942
Pharmacokinetics of [C-14]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral doseto HIV-1-infected adults: a mass balance study
Authors: McDowell, JA Chittick, GE Ravitch, JR Polk, RE Kerkering, TM Stein, DS
Citation: Ja. Mcdowell et al., Pharmacokinetics of [C-14]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral doseto HIV-1-infected adults: a mass balance study, ANTIM AG CH, 43(12), 1999, pp. 2855-2861
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults - AIDS clinical trials group protocols 150 and 258
Authors: Gulick, RM McAuliffe, V Holden-Wiltse, J Crumpacker, C Liebes, L Stein, DS Meehan, P Hussey, S Forcht, J Valentine, FT
Citation: Rm. Gulick et al., Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults - AIDS clinical trials group protocols 150 and 258, ANN INT MED, 130(6), 1999, pp. 510-514
Risultati: 1-17 |